Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Pluristem stock

Learn how to easily invest in Pluristem stock.

Pluristem is a biotechnology business based in the US. Pluristem shares (PSTI) are listed on the NASDAQ and all prices are listed in US Dollars. Pluristem employs 153 staff and has a trailing 12-month revenue of around $234,000.

How to buy shares in Pluristem

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PSTI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Pluristem stock price (NASDAQ: PSTI)

Use our graph to track the performance of PSTI stocks over time.

Pluristem shares at a glance

Information last updated 2022-10-02.
Latest market close$0.67
52-week range$0.66 - $3.19
50-day moving average $1.19
200-day moving average $1.76
Wall St. target price$3.50
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.46

Buy Pluristem shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pluristem stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pluristem price performance over time

Historical closes compared with the close of $0.67 from 2022-09-26

1 week (2022-09-26) 0.67
1 month (2022-09-02) -24.73%
3 months (2022-07-05) -48.06%
6 months (2022-04-05) -69.27%
1 year (2021-10-05) -73.52%
2 years (2020-10-05) -93.60%
3 years (2019-10-04) 3.66
5 years (2017-10-04) 1.5

Pluristem financials

Revenue TTM $234,000
Gross profit TTM $23,000
Return on assets TTM -37.35%
Return on equity TTM -86.55%
Profit margin 0%
Book value $1.18
Market capitalisation $32.3 million

TTM: trailing 12 months

Pluristem share dividends

We're not expecting Pluristem to pay a dividend over the next 12 months.

Have Pluristem's shares ever split?

Pluristem's shares were split on a 1:10 basis on 25 July 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pluristem shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pluristem shares which in turn could have impacted Pluristem's share price.

Pluristem share price volatility

Over the last 12 months, Pluristem's shares have ranged in value from as little as $0.6556 up to $3.19. A popular way to gauge a stock's volatility is its "beta".

PSTI.US volatility(beta: 1.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pluristem's is 1.9127. This would suggest that Pluristem's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Pluristem overview

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions.

Frequently asked questions

What percentage of Pluristem is owned by insiders or institutions?
Currently 7.281% of Pluristem shares are held by insiders and 12.805% by institutions.
How many people work for Pluristem?
Latest data suggests 153 work at Pluristem.
When does the fiscal year end for Pluristem?
Pluristem's fiscal year ends in June.
Where is Pluristem based?
Pluristem's address is: Building No. 5, Haifa, Israel, 3508409
What is Pluristem's ISIN number?
Pluristem's international securities identification number is: US72940R3003
What is Pluristem's CUSIP number?
Pluristem's Committee on Uniform Securities Identification Procedures number is: 72940P106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site